<p>StockNews.com 的投资分析师在周一发布给投资者的研究报告中开始覆盖蓝鸟生物（NASDAQ:BLUE - 获取免费报告）的股票。该经纪公司对这家生物技术公司的股票给予了 “卖出” 评级。</p>
<ul>
<li>Beam Therapeutics 因基因治疗许可支付而大幅上涨</li>
</ul>
<p>其他几位研究分析师最近也对 BLUE 发表了看法。巴克莱将蓝鸟生物的目标价从 4.00 美元下调至 2.00 美元，并在周五的研究报告中对该公司给予了 “增持” 评级。罗伯特·W·贝尔德将蓝鸟生物的目标价从 7.00 美元下调至 6.00 美元，并在 8 月 15 日的研究报告中对该股票给予了 “跑赢大盘” 评级。美国银行将蓝鸟生物的股票评级从 “买入” 下调至 “中性”，并在周五的研究报告中将该公司的目标价从 3.00 美元下调至 0.50 美元。Cantor Fitzgerald 在 9 月 16 日的报告中重申了对蓝鸟生物股票的 “中性” 评级。最后，摩根大通在周五的研究报告中将蓝鸟生物的股票评级从 “中性” 下调至 “减持”。三位股票研究分析师对该股票给予了卖出评级，七位给予了持有评级，两位给予了买入评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，平均目标价为 3.03 美元。</p>
<p><strong>查看我们对蓝鸟生物的最新分析</strong></p>
<h2>蓝鸟生物股价下跌 11.5%</h2>
<ul>
<li>MarketBeat 周回顾 – 2/26 - 3/1</li>
</ul>
<p>周一，BLUE 股票开盘价为 0.32 美元。该股票的市值为 6221 万美元，市盈率为 -0.17，贝塔值为 0.76。该公司的速动比率为 0.57，流动比率为 0.68，债务与股本比率为 0.37。蓝鸟生物的 52 周低点为 0.32 美元，52 周高点为 5.53 美元。该公司的 50 日简单移动平均线为 0.49 美元，200 日简单移动平均线为 0.78 美元。</p>
<p>蓝鸟生物（NASDAQ:BLUE - 获取免费报告）最近一次发布财报是在 9 月 13 日，生物技术公司报告该季度每股收益为 -0.36 美元。该季度的收入为 1857 万美元。蓝鸟生物的净利润率为 -565.74%，股本回报率为 -238.15%。分析师平均预测蓝鸟生物在当前财年将发布 -1.41 美元的每股收益。</p>
<h2>机构资金流入和流出</h2>
<ul>
<li>蓝鸟生物股票显示出成为多倍收益股的潜力</li>
</ul>
<p>一些机构投资者最近对 BLUE 的持仓进行了调整。阿勒格尼金融集团在第二季度购买了蓝鸟生物的新头寸，价值 25,000 美元。Verition 基金管理公司在第三季度收购了蓝鸟生物的股份，价值约 42,000 美元。贝叶斯资本管理公司在第一季度购买了蓝鸟生物的新头寸，价值约 52,000 美元。SG 美洲证券公司在第三季度将其在蓝鸟生物的持股增加了 152.4%。SG 美洲证券公司现在拥有 122,855 股该生物技术公司的股票，价值 64,000 美元，此前在上个季度购买了额外的 74,185 股。最后，Price T Rowe Associates Inc. MD 在第一季度将其在蓝鸟生物的持仓增加了 113.7%。Price T Rowe Associates Inc. MD 现在拥有 54,714 股该生物技术公司的股票，价值 71,000 美元，此前在上个季度购买了额外的 29,113 股。87.43% 的股票由机构投资者持有。</p>
<h2>蓝鸟生物公司简介</h2>
<p>(获取免费报告)</p>
<p>蓝鸟生物公司是一家生物技术公司，研究、开发和商业化用于治疗严重遗传疾病的基因疗法。其针对严重遗传疾病的产品候选包括 ZYNTEGLO（betibeglogene autotemcel）用于治疗输血依赖性β-地中海贫血；lovotibeglogene autotemcel 用于治疗镰状细胞病（SCD）；以及 SKYSONA（elivaldogene autotemcel）用于治疗脑性肾上腺白质营养不良症。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票，胜过蓝鸟生物</li>
<li>电动车股票及其获利方式</li>
<li>沃伦·巴菲特、凯西·伍德持有 Nu Holdings，你应该买吗？</li>
<li>美股下跌 23% 后：是否是买入的好时机？</li>
<li>纳斯达克是什么？完整概述及历史</li>
<li>ORIC：与两家制药巨头合作，分析师预计有 +100% 的上涨空间</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxVRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxVRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<p>→ ❗ 请回复确认！ (来自市场背后)(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDU0Mw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDU0Mw"/></p>
<h2>你现在应该投资 1,000 美元在蓝鸟生物吗？</h2>
<p>在你考虑蓝鸟生物之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而蓝鸟生物并不在名单上。</p>
<p>虽然蓝鸟生物目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

蓝鸟生物

<p>StockNews.com 已经开始对蓝鸟生物（NASDAQ:BLUE）进行覆盖，给予其 “卖出” 评级。其他分析师也调整了他们的评级，巴克莱设定了 “增持” 评级，而美国银行则将其下调至 “中性”。目前，该股票的共识评级为 “持有”，平均目标价为 3.03 美元。蓝鸟生物报告了 565.74% 的负净利润率，预计本财年每股收益为 -1.41 美元。机构投资者持有该股票的 87.43%</p>

<p>Investment analysts at StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE - Get Free Report) in a research note issued to investors on Monday. The brokerage set a &#34;sell&#34; rating on the biotechnology company's stock.</p>
<div class="lb-trans"><p>StockNews.com 的投资分析师在周一发布给投资者的研究报告中开始覆盖蓝鸟生物（NASDAQ:BLUE - 获取免费报告）的股票。该经纪公司对这家生物技术公司的股票给予了 “卖出” 评级。</p>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治疗许可支付而大幅上涨</li>
</ul>
</div><p>Several other research analysts also recently weighed in on BLUE. Barclays cut their target price on shares of bluebird bio from $4.00 to $2.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday. Robert W. Baird cut their price objective on bluebird bio from $7.00 to $6.00 and set an &#34;outperform&#34; rating on the stock in a research report on Thursday, August 15th. Bank of America downgraded shares of bluebird bio from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and decreased their target price for the company from $3.00 to $0.50 in a research note on Friday. Cantor Fitzgerald restated a &#34;neutral&#34; rating on shares of bluebird bio in a report on Monday, September 16th. Finally, JPMorgan Chase &amp; Co. cut shares of bluebird bio from a &#34;neutral&#34; rating to an &#34;underweight&#34; rating in a research report on Friday. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and an average price target of $3.03.</p>
<div class="lb-trans"><p>其他几位研究分析师最近也对 BLUE 发表了看法。巴克莱将蓝鸟生物的目标价从 4.00 美元下调至 2.00 美元，并在周五的研究报告中对该公司给予了 “增持” 评级。罗伯特·W·贝尔德将蓝鸟生物的目标价从 7.00 美元下调至 6.00 美元，并在 8 月 15 日的研究报告中对该股票给予了 “跑赢大盘” 评级。美国银行将蓝鸟生物的股票评级从 “买入” 下调至 “中性”，并在周五的研究报告中将该公司的目标价从 3.00 美元下调至 0.50 美元。Cantor Fitzgerald 在 9 月 16 日的报告中重申了对蓝鸟生物股票的 “中性” 评级。最后，摩根大通在周五的研究报告中将蓝鸟生物的股票评级从 “中性” 下调至 “减持”。三位股票研究分析师对该股票给予了卖出评级，七位给予了持有评级，两位给予了买入评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，平均目标价为 3.03 美元。</p>
</div><p><strong>View Our Latest Analysis on bluebird bio</strong></p>
<div class="lb-trans"><p><strong>查看我们对蓝鸟生物的最新分析</strong></p>
</div><h2>bluebird bio Trading Down 11.5 %</h2>
<div class="lb-trans"><h2>蓝鸟生物股价下跌 11.5%</h2>
</div><ul>
<li>MarketBeat Week in Review – 2/26 - 3/1</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 2/26 - 3/1</li>
</ul>
</div><p>Shares of BLUE stock opened at $0.32 on Monday. The stock has a market cap of $62.21 million, a P/E ratio of -0.17 and a beta of 0.76. The company has a quick ratio of 0.57, a current ratio of 0.68 and a debt-to-equity ratio of 0.37. bluebird bio has a fifty-two week low of $0.32 and a fifty-two week high of $5.53. The business has a fifty day simple moving average of $0.49 and a 200-day simple moving average of $0.78.</p>
<div class="lb-trans"><p>周一，BLUE 股票开盘价为 0.32 美元。该股票的市值为 6221 万美元，市盈率为 -0.17，贝塔值为 0.76。该公司的速动比率为 0.57，流动比率为 0.68，债务与股本比率为 0.37。蓝鸟生物的 52 周低点为 0.32 美元，52 周高点为 5.53 美元。该公司的 50 日简单移动平均线为 0.49 美元，200 日简单移动平均线为 0.78 美元。</p>
</div><p>bluebird bio (NASDAQ:BLUE - Get Free Report) last posted its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. The business had revenue of $18.57 million for the quarter. bluebird bio had a negative net margin of 565.74% and a negative return on equity of 238.15%. On average, analysts forecast that bluebird bio will post -1.41 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>蓝鸟生物（NASDAQ:BLUE - 获取免费报告）最近一次发布财报是在 9 月 13 日，生物技术公司报告该季度每股收益为 -0.36 美元。该季度的收入为 1857 万美元。蓝鸟生物的净利润率为 -565.74%，股本回报率为 -238.15%。分析师平均预测蓝鸟生物在当前财年将发布 -1.41 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>bluebird bio Stock Signals Potential to be a Multi-bagger</li>
</ul>
<div class="lb-trans"><ul>
<li>蓝鸟生物股票显示出成为多倍收益股的潜力</li>
</ul>
</div><p>A number of institutional investors have recently made changes to their positions in BLUE. Allegheny Financial Group LTD bought a new position in bluebird bio during the second quarter worth $25,000. Verition Fund Management LLC acquired a new stake in shares of bluebird bio during the 3rd quarter worth about $42,000. Bayesian Capital Management LP bought a new position in bluebird bio during the 1st quarter valued at about $52,000. SG Americas Securities LLC boosted its stake in bluebird bio by 152.4% in the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 74,185 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of bluebird bio by 113.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company's stock worth $71,000 after purchasing an additional 29,113 shares in the last quarter. 87.43% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近对 BLUE 的持仓进行了调整。阿勒格尼金融集团在第二季度购买了蓝鸟生物的新头寸，价值 25,000 美元。Verition 基金管理公司在第三季度收购了蓝鸟生物的股份，价值约 42,000 美元。贝叶斯资本管理公司在第一季度购买了蓝鸟生物的新头寸，价值约 52,000 美元。SG 美洲证券公司在第三季度将其在蓝鸟生物的持股增加了 152.4%。SG 美洲证券公司现在拥有 122,855 股该生物技术公司的股票，价值 64,000 美元，此前在上个季度购买了额外的 74,185 股。最后，Price T Rowe Associates Inc. MD 在第一季度将其在蓝鸟生物的持仓增加了 113.7%。Price T Rowe Associates Inc. MD 现在拥有 54,714 股该生物技术公司的股票，价值 71,000 美元，此前在上个季度购买了额外的 29,113 股。87.43% 的股票由机构投资者持有。</p>
</div><h2>bluebird bio Company Profile</h2>
<div class="lb-trans"><h2>蓝鸟生物公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.</p>
<div class="lb-trans"><p>蓝鸟生物公司是一家生物技术公司，研究、开发和商业化用于治疗严重遗传疾病的基因疗法。其针对严重遗传疾病的产品候选包括 ZYNTEGLO（betibeglogene autotemcel）用于治疗输血依赖性β-地中海贫血；lovotibeglogene autotemcel 用于治疗镰状细胞病（SCD）；以及 SKYSONA（elivaldogene autotemcel）用于治疗脑性肾上腺白质营养不良症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than bluebird bio</li>
<li>EV Stocks and How to Profit from Them</li>
<li>Warren Buffett, Cathie Wood Own Nu Holdings, Should You?</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?</li>
<li>What is the Nasdaq? Complete Overview with History</li>
<li>ORIC: Working with Two Pharma Giants, Analysts See +100% Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过蓝鸟生物</li>
<li>电动车股票及其获利方式</li>
<li>沃伦·巴菲特、凯西·伍德持有 Nu Holdings，你应该买吗？</li>
<li>美股下跌 23% 后：是否是买入的好时机？</li>
<li>纳斯达克是什么？完整概述及历史</li>
<li>ORIC：与两家制药巨头合作，分析师预计有 +100% 的上涨空间</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxVRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BLUE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><p>→ ❗ RSVP please! (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ ❗ 请回复确认！ (来自市场背后)(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDU0Mw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10543&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in bluebird bio right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在蓝鸟生物吗？</h2>
</div><p>Before you consider bluebird bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑蓝鸟生物之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bluebird bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而蓝鸟生物并不在名单上。</p>
</div><p>While bluebird bio currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然蓝鸟生物目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

蓝鸟生物（NASDAQ:BLUE）现已被 StockNews.com 覆盖